Symbiotec Pharmalab Ltd (SYMBIOTEC) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Symbiotec Pharmalab Ltd on NSE and BSE, with an AI summary of each filing.
Earnings Conference Call / Analysts Meet to discuss the financial performance and business updates for the quarter and half year ended September 30, 2026 (Q2FY27). The Earnings Conference ....
Intimation · 06 Nov 2026, 9:30 am
Symbiotec Pharmalab Schedules Q2 & H1FY27 Earnings Call for 6th Nov'26 Symbiotec Pharmalab Limited will host its Q2 and H1FY27 earnings conference call on 6th Nov'26 at 09:30 AM IST to discuss financial performance and business updates for the period ended 30th Sep'26. Hosted by Avendus Spark, the virtual meeting will feature CMD Anil Satwani and CFO Raghavender Ramachandran representing the company management.
To consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30 September 2026, along with Limited Review Report.
Intimation · 05 Nov 2026, 5:30 am
Symbiotec Pharmalab Limited has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 05 Nov 2026, 5:30 am
Symbiotec Pharmalab Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve To consider and approve ....
Intimation · 05 Nov 2026, 5:30 am
Symbiotec Pharmalab Board to Review Q2 FY27 Results on 5th Nov'26 Symbiotec Pharmalab Limited has scheduled its Board of Directors meeting for 5th Nov'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26, alongside the Limited Review Report. In compliance with insider trading regulations, the company's trading window for dealing in its securities by designated persons and their immediate relatives remains closed until 48 hours following the official declaration of the financial results.
The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 16, 2026 for Anil Satwani, ....
Encumbered Shares - Invocation / Release · 16 Oct 2026, 10:52 pm
Symbiotec Pharmalab Promoters Submit Revised Share Pledge Disclosures Symbiotec Pharmalab submitted revised SEBI SAST disclosures on 16th Oct'26 correcting lender details for promoter share pledges re-created between 8th Sep'26 and 10th Sep'26 in favour of Nomura Capital (India) and Beacon Trusteeship. Pledges secure debenture issuances across promoter entities: Anil Satwani pledged 4,50,896 shares (0.70%), Sushil Satwani 3,13,938 shares (0.49%), Kashish Satwani 5,00,896 shares (0.78%), Satwani Holdings LLP 22,27,734 shares (3.47%), Kashish and Anil Satwani Family Trust 3,50,000 shares (0.54%), Arjun Anil Satwani Family Trust 21,99,104 shares (3.42%), and Krishna Anil Satwani Family Trust 21,99,104 shares (3.42%).
Symbiotec''s Wholly Owned Subsidiary Knovea Pharmaceutical enters into strategic commercialization agreement with a leading global pharmaceutical company for Dual Chamber Vial (''DCV'') ....
Others (Uncategorized) · 01 Oct 2026, 1:39 am
Symbiotec Subsidiary Signs U.S. Commercialization Deal for Injectable Products Symbiotec Pharmalab’s wholly owned subsidiary, Knovea Pharmaceutical, has signed a definitive agreement with a leading global pharmaceutical company on 30th Sep'26. The partner gains exclusive rights to commercialize and distribute two Dual Chamber Vial (DCV) injectable products in the U.S., targeting an addressable market estimated at ~$288 million. Knovea will manage development, regulatory filings, manufacturing, and supply. In return, Knovea will receive development, regulatory, and commercial milestone payments, alongside ongoing post-launch profit-sharing.
Symbiotec Pharmalab Limited receives Establishment Inspection Report ("EIR") from U.S. FDA for its manufacturing facility in Pithampur ("SEZ") with VAI classification.
Others (Uncategorized) · 29 Sept 2026, 4:22 pm
Symbiotec Pharmalab Receives US FDA EIR with VAI Status for Pithampur Facility Symbiotec Pharmalab Limited received an Establishment Inspection Report from the U.S. FDA on 29th Sep'26 for its manufacturing facility located at Pithampur (SEZ), Madhya Pradesh. The regulatory agency classified the inspection outcome as Voluntary Action Indicated (VAI). This follows the regulatory audit conducted at the manufacturing site between 10th Aug'26 and 14th Aug'26, successfully resolving the inspection cycle and supporting ongoing regulatory compliance for U.S. market supplies.
Transcript of the Earnings conference call for Analysts and Investors for Q1 Financial Year 2027
Transcript · 28 Sept 2026, 11:59 pm
Audio Recording Of Earnings Conference Call For Analysts And Investors held today September 22, 2026.
Audio / Video · 22 Sept 2026, 8:21 pm
Symbiotec Pharmalab Releases Q1 FY27 Earnings Conference Call Audio Recording Symbiotec Pharmalab Limited has made available the audio recording link for its earnings conference call held on 22nd Sep'26. The call discussed the company's operational and financial performance for Q1 ended 30th Jun'26. The recording is accessible to investors and analysts via the company's investor relations portal and direct host link.
Announcement under Regulation 30 (LODR) - Press Release
Press Release · 22 Sept 2026, 1:20 am
Symbiotec Pharmalab Reports Q1FY27 Financial Results with Strong Core API Performance Symbiotec Pharmalab reported consolidated Q1FY27 revenue of Rs. 218.2 crs versus Rs. 203.2 crs in Q1FY26. Consolidated EBIDTA and PAT stood at Rs. 45.2 crs and Rs. 14.1 crs, impacted by Rs. 35 crs in operating expenses and depreciation from pre-revenue growth initiatives. Core API business grew 6% YoY to Rs. 215.3 crs, delivering ~30% EBIDTA margins. The company filed its first DCV ANDA in Sep'26, secured long-term CDMO contracts, and reduced net debt post-IPO to ~Rs. 326 crs as of 20th Sep'26.
Announcement under Regulation 30 (LODR) - Investor Presentation
Investor Presentation · 22 Sept 2026, 1:17 am
Symbiotec Pharmalab Q1FY27 Performance and Business Expansion Update Symbiotec Pharmalab debuted on the BSE and NSE on 1st Sep'26 following a Rs. 1,757 Cr IPO at Rs. 988 per share. For Q1FY27, consolidated revenue rose 7% YoY to Rs. 218.2 Cr, while reported EBITDA fell to Rs. 45.2 Cr (21% margin) and PAT declined to Rs. 14.1 Cr, impacted by Rs. 35 Cr in unabsorbed opex and depreciation from new pre-revenue businesses. Over 60% of its Rs. 1,475 Cr gross capex is slated to generate commercial revenue over the next 6–12 months.
Symbiotec Pharmalab Limited has informed the Exchange regarding Outcome of Board Meeting held on September 21, 2026.
Outcome · 22 Sept 2026, 1:08 am
With reference to the captioned subject, this is to inform you that Board Meeting held on September 21, 2026, have inter alia consider and approved the unaudited Standalone & Consolidated ....
Financial Result · 22 Sept 2026, 12:37 am
Symbiotec Pharmalab Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
Outcome · 22 Sept 2026, 12:14 am
Dear Sir / Madam, With reference to the captioned subject, this is to inform you that the Board of Directors of the Company at its meeting held today i.e., Monday, September 21, 2026, ....
Outcome · 22 Sept 2026, 12:02 am
Symbiotec Pharmalab Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Million) ■ Revenue: 2,182 (+7.4% YoY | -11.1% QoQ) ■ EBITDA: 452 (-22.0% YoY | -27.2% QoQ) ■ EBITDA Margin (%): 20.7 (-781 bps YoY | -460 bps QoQ) ■ PAT: 141 (-53.0% YoY | -48.9% QoQ) ■ EPS (INR): 2.24 (-58.1% YoY | -52.9% QoQ)
Dear Sir / Madam, Pursuant to above referred Listing Regulations, we enclose herewith the details of the 'Earnings Conference Call / Analysts Meet' to discuss the financial performance ....
Intimation · 22 Sept 2026, 10:00 am
Symbiotec Pharmalab Schedules Q1FY27 Earnings Call for 22nd Sep'26 Symbiotec Pharmalab Limited will host its Q1FY27 earnings conference call on 22nd Sep'26 at 10:00 AM IST to discuss financial performance and business updates for the quarter ended 30th Jun'26. Organized by JM Financial Institutional Securities Limited, the call will feature key management participants, including Promoter & CMD Anil Satwani and Chief Financial Officer Raghavender Ramachandran. Universal dial-in access is available via +91 22 6280 1366 and +91 22 7115 8267, alongside international toll-free numbers for the USA, UK, Singapore, and Hong Kong.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 11, 2026 for Anil Satwani, Sushil ....
Encumbered Shares - Invocation / Release · 12 Sept 2026, 3:57 pm
Symbiotec Pharmalab Promoters Disclose Re-Creation of Share Pledges Post-IPO Symbiotec Pharmalab Limited’s promoter and promoter group entities reported the re-creation of share pledges in favor of Beacon Trusteeship Limited across 8th–10th Sep'26. The pledges secure issued debentures under a pledge agreement originally dated 10th Dec'25. They were temporarily released to implement mandatory pre-IPO promoter lock-in requirements per SEBI ICDR Regulations and re-instated post-IPO. The administrative filings encompass encumbrances across Satwani Holdings LLP (3.47%), Arjun Anil Satwani Family Trust (3.42%), Krishna Anil Satwani Family Trust (3.42%), Kashish Satwani (0.78%), Anil Satwani (0.70%), Kashish and Anil Satwani Family Trust (0.54%), and Sushil Satwani (0.49%), representing no effective change in pledged holdings.
To consider and approve the financial results for the period ended Jun 30, 2026
Intimation · 29 Jun 2026, 5:30 am
Symbiotec Pharmalab Limited has informed the Exchange about Board Meeting to be held on 21-Sep-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended June 2026 .
Intimation · 21 Sept 2026, 5:30 am
Symbiotec Pharmalab Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/09/2026 ,inter alia, to consider and approve To consider and approve ....
Intimation · 21 Sept 2026, 5:30 am
Symbiotec Pharmalab Board to Consider Q1 FY27 Results on 21st Sep'26 Symbiotec Pharmalab Limited has scheduled a Board of Directors meeting on 21st Sep'26 to consider and approve the unaudited standalone and consolidated financial results, along with the Limited Review Report, for the quarter ended 30th Jun'26. Additionally, the trading window for dealing in company securities by designated persons and their immediate relatives remains closed until 48 hours following the formal declaration of the results.
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Beacon Trusteeship Ltd
Acquisition/ Disposal of Shares · 11 Sept 2026, 6:00 pm
Beacon Trusteeship Discloses 5.44% Equity Encumbrance in Symbiotec Pharmalab Beacon Trusteeship Limited, acting as debenture trustee for NCDs issued by Satwani Holdings (India) Private Limited, created an encumbrance over 3,493,464 equity shares of Symbiotec Pharmalab Limited. This represents 5.44% of total share capital and 5.43% of diluted share capital. The pledged shares, created between 8th Sep'26 and 9th Sep'26, comprise holdings from promoter group members: Satwani Holding LLP (3.47%), Kashish Satwani (0.78%), Anil Satwani (0.70%), and Sushil Satwani (0.49%) to secure debt obligations under the debenture trust deed.
Update on Intimation under Regulation 8(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.
Others (Uncategorized) · 03 Sept 2026, 7:17 pm
Symbiotec Pharmalab Adopts Code of Fair Disclosure for UPSI Under SEBI Regulations On 3rd Sep'26, Symbiotec Pharmalab filed its Code of Practices for Fair Disclosure of Unpublished Price Sensitive Information (UPSI), effective 15th Dec'25. Mandated by SEBI, the policy enforces prompt, universal dissemination of price-sensitive data and strict confidentiality on a need-to-know basis for legitimate business purposes. To ensure strict compliance and transparency, the Board appointed a Chief Investor Relations Officer (CIRO) reporting directly to the CFO. The CIRO will exclusively oversee UPSI disclosure, verify market rumors, and manage all official communications with stock exchanges and media.
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mirae Asset Mutual Fund
Acquisition/ Disposal of Shares · 02 Sept 2026, 10:35 pm
Mirae Asset Mutual Fund Acquires 5.44% Stake in Symbiotec Pharmalab On 1st Sep'26, Mirae Asset Mutual Fund acquired 3,497,420 equity shares of Symbiotec Pharmalab Ltd via an open market transaction, representing a 5.44% stake. Prior to this purchase, the fund held 498,019 shares, or a 0.78% stake. Following the transaction, Mirae Asset's total holding in Symbiotec Pharmalab significantly increased to 3,995,439 shares, equating to a 6.22% total voting capital stake (6.21% on a fully diluted basis). This block purchase effectively triggers SEBI disclosure requirements for crossing the key 5% ownership threshold.
Intimation under Regulation 8(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.
Others (Uncategorized) · 01 Sept 2026, 9:11 pm
Symbiotec Submits Code for Fair Disclosure of Price Sensitive Information Symbiotec Pharmalab informed exchanges on 01-Sep'26 that it has submitted its Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information. This filing is in compliance with Regulation 8(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. The code governs the handling and disclosure of material non-public information, fulfilling a key regulatory requirement. The company's Scrip Symbol on NSE is SYMBIOTEC and its BSE Scrip Code is 544889.
Disclosure regarding authority to determine materiality of event or information.
Others (Uncategorized) · 01 Sept 2026, 9:03 pm
Symbiotec Authorizes Key Personnel for Materiality Determination As per SEBI regulations, Symbiotec Pharmalab has authorized its Key Managerial Personnel to determine the materiality of events for stock exchange disclosures, effective 01 Sep'26. The authorized personnel are Anil Satwani (Chairman & MD), Raghavender Ramachandran (CFO), and Salil Jain (Company Secretary & Compliance Officer). This action formalizes the company's disclosure protocol and designates the key points of contact for material corporate information.